Adam Lenkowsky's most recent trade in Bristol-Myers Squibb Co. was a trade of 1,373 Common Stock, $0.10 par value done . Disclosure was reported to the exchange on May 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2026 | 1,373 | 20,508 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2026 | 1,373 | 1,375 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.22 per share. | 01 May 2026 | 599 | 19,706 (0%) | 0% | 58.2 | 34,874 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 01 May 2026 | 203 | 20,305 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 48,980 | 48,980 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 32,653 | 32,653 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 12,002 | 26,104 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 12,002 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 8,241 | 25,327 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 8,241 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2026 | 5,893 | 20,211 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2026 | 4,046 | 21,281 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.13 per share. | 10 Mar 2026 | 3,125 | 17,086 (0%) | 0% | 60.1 | 187,906 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.13 per share. | 10 Mar 2026 | 2,146 | 19,135 (0%) | 0% | 60.1 | 129,039 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 2,000 | 15,231 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 2,000 | 2,001 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 1,828 | 14,267 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 1,828 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.13 per share. | 10 Mar 2026 | 913 | 14,102 (0%) | 0% | 60.1 | 54,899 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.13 per share. | 10 Mar 2026 | 831 | 13,231 (0%) | 0% | 60.1 | 49,968 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2026 | 216 | 15,015 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2026 | 205 | 14,062 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Nov 2025 | 22,568 | 22,568 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 01 May 2025 | 1,373 | 2,748 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 47,197 | 47,197 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 31,464 | 31,464 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 10,955 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 10,955 | 20,017 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 4,040 | 15,977 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 3,538 | 12,439 (0%) | 0% | 63.1 | 223,283 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,000 | 4,001 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,000 | 10,252 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 1,904 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 1,904 | 8,554 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 1,825 | 1,828 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 1,825 | 9,341 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 907 | 7,516 (0%) | 0% | 63.1 | 57,241 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 849 | 9,062 (0%) | 0% | 63.1 | 53,580 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 771 | 8,252 (0%) | 0% | 63.1 | 48,658 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 341 | 9,911 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 318 | 9,023 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 131 | 8,423 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 01 May 2024 | 1,373 | 4,121 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 31,347 | 31,347 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 20,898 | 20,898 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 11,416 | 13,859 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 11,416 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 3,974 | 9,885 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 3,235 | 6,650 (0%) | 0% | 53.8 | 174,011 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 2,000 | 6,001 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 1,902 | 3,341 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 1,902 | 1,904 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 1,825 | 3,653 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 1,698 | 2,224 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 1,698 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 570 | 2,443 (0%) | 0% | 53.8 | 30,660 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 518 | 1,439 (0%) | 0% | 53.8 | 27,863 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 328 | 3,013 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 267 | 1,957 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2023 | 1,077 | 0 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2023 | 1,077 | 1,077 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.66 per share. | 03 Jun 2023 | 551 | 526 (0%) | 0% | 65.7 | 36,179 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 8,241 | 8,241 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Adam Lenkowsky | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 5,494 | 5,494 | - | - | Market Share Units |